

74
OIFA

JUL 02 2001

CERTIFICATION

I, Akemi TAKEOKA, whose address is Nichimen Building 2F.,
2-2, Nakanoshima 2-chome, Kita-ku, Osaka-shi, Osaka, Japan,
hereby certify that I am the translator of the attached document,
namely,

U.S. Patent Application Ser. No. 09/757,655

that I am familiar with both the Japanese language and the
English language, and that the translation is a true and correct
translation from the Japanese language to the English language to
the best of my knowledge and belief.

This 25th day of April, 2001

Akemi Takeoka

Akemi TAKEOKA

014E
JUL 02 2001

A PEPTIDE HAVING AN AFFINITY FOR gp120

TECHNICAL FIELD

This invention relates to a peptide which has an affinity for gp120, HIV (human immunodeficiency virus) envelope protein.

BACKGROUND ART

The therapy for HIV infection is usually chemotherapy, such as the nucleotide derivative AZT (3'-azido-3'-deoxythymidine). This AZT therapy or protease inhibitor, which was later developed, prolongs the life of HIV patients, but there are some problems, these are derived from the chemotherapy itself.

There problems are shown as follows; The first is chronic poisoning due to long term administration, the second is the appearance of an HIV virus resistant to the medicine during the therapy, the third is the appearance of malignant tumors in prolongation of the HIV patient's life, the fourth is that the recovery of the immune system can not be monitored, the fifth is that there not being a method to monitor treatment effect, etc. Since such chemotherapy is not basic therapy for HIV infections, most people anticipate the development of a vaccine.

Generally, the vaccine is an inactive treatment (in active vaccine) of a microbe of viruses; a weak activity virus which loses pathogenesis or a pseudo virus (live vaccine) which has no fatal effects to humans. However, although HIV itself is natively a weak

activity virus, it is well known to stay long after having once invaded the body. In addition, the host cell of HIV is mainly a lymphocyte, which controls the immune system; furthermore, HIV spreads over hemophilic patients through blood-preparation. From these finding, even if it is assumed that we selected either an in-active or a weak vaccine, the development of an HIV vaccine has many problems with safety.

Accordingly, an HIV vaccine is being developed which utilizes a part of the HIV envelope protein and inhibits further infection.

From such an idea, many researchers performed an epitope analysis of gp 120 in the HIV enveloped protein, and then, watched the V3 region (3rd hypervariable region) of gp120 as an epitope. But it was a true hypervariable region [Palker T.J., et al., Proc. Natl. Acad. Sci. USA 85:2709-2713, 1988; Rusche J.R., et al., ibid 85:3198-3202,1988; Gouddsmi J., et all., ibid 85:4478-4482.1988; Matsushita S., et al., J Virol. 62:2107-2114,1988]. After this, a vaccine which used a part of this region as antigen was administrated to an HIV infected monkey as an infection inhibitory experiment, but the effect has not yet been reported.

As well as this, Tam et al. devised further antigenecity for the above-mentioned peptide antigen (Tam et. al., Japanese patent publication(Tokuhyo) No. H 3-503539), but have not yet had success because in most parts of the V region, particularly in the V3 which is a convenient region for antibody preparation, mutation or deletion occurs.

In addition, a neutralized antibody, which inhibits the infection against lymphocyte, is developed. For example, in Japanese Patent Application No. 63-171385, after the production of a monoclonal antibody by using a part of the above mentioned peptide as antigen, a method is reported, which produces anti HIV chimera antibodies on

hybridization due to genetic engineering at the level of the protein as the Fab' itself. But, although with such neutralizing antibodies it is possible to inhibit HIV infection to the lymphocyte at laboratory level, an antibody that can be used practically has not yet been developed.

As mentioned above, chemotherapy has some problems; drug tolerance in the virus and side effects in the host, another idea to solve the problem of removing the virus from the body is by plasmapheresis. Although this method to remove the HIV virus by using a pore size membrane filter (smaller than virus size) for plasmapheresis has been definitely proposed it is not yet possible to make a uniform pore size membrane. It is also possible that the pores will become clogged during plasmapheresis resulting in the deterioration of the membrane due to pressure. As mentioned above there are many technical problems which have to be settled. So, a method to use CD4 derived from human lymphocyte having specific affinity to HIV, as absorbed carrier in column for plasmapheresis is also proposed. It cannot be used as a medical procedure because of the lost affinity due to decay by autoclave treatment. In addition, there are also methods using thermostable molecules, a high molecule polymer or color ligand as an affinity carrier to HIV. However, as these molecules do not originally have specific binding ability to HIV, they cannot be used because they bind to blood ingredients faster than to HIV.

In this way, aiming at the development of a HIV treatment medicine, research to produce a vaccine and neutrizing antibody is flourishing, but useful medicine has not yet been developed.

The inventors paid attention to this present situation and developed a superior

peptide to have the same degree or more affinity for gp120 compared to antibodies and to be resistant to autoclave treatment, and have already made a patent application (Japanese Patent Application No. H 8-351474 and Japanese Patent Application No. 8-351475). This peptide basically consists of a three amino acid sequence, but from a study of the sequel, we found that an affinity to gp120 of this peptide deteriorated by number and a kind of the amino acid which ranged in it. So, we knew that we needed to develop a more stable peptide.

DISCLOSURE OF THE INVENTION

In view of the above, an object of this invention is to provide a novel peptide which has an affinity for gp120, HIV envelope protein, with excellent stability, and a variety of usabilities using the peptide.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph that shows result of EXAMPLE 8.

FIG. 2 is a photograph by electron microscope that shows the result of EXAMPLE 15.

BEST MODE FOR CARRYING OUT THE INVENTION

The No.1 peptide in this invention that could solve the above subject;

A peptide having an affinity to gp120 represented by formula (1):

H-A1-A2-A3-A4-A5-R

(in the formula,

H means hydrogen,

A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine residue,

A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine, leucine, or tyrosine residue,

A3 is lysine, valine, aspartic acid, arginine, alanine, or Tryptophan residue,

A4 is alanine, tryptophan, or glycine residue

A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue,

R is OH derived from carboxyl group or NH₂ derived from acid amide group).

Accordingly, the No. 1 peptide in this invention is a 5 amino acid sequence that was constituted by A1, A2, A3, A4 and A5 as described above, and all of the peptide including such amino acid sequences contained by the range of this invention. Thus, a peptide having an affinity to gp120 represented by

Formula(2): A1'-A2-A3-A4-A5-R

(in the formula,

A1' means aspartic acid, lysine, valine, glutamic acid,

glycine, aspragine, or tyrosine reidue, or polypeptide residue that an arbitrary amino acid stood in line in the N-terminal side from this amino acid, A2, A3, A4, A5 and R has the same meaning as above)

or

Formula (3): H-A1-A2-A3-A4-A5'-R

(in the formula,

A5' means glycine, alanine, valine, leucine, isoleucine,

threonine, methionine, asparagine, glutamine,

histidine, lysine,, arginine, phenylalanine, tryptophan,

proline, or tyrosine residue, or polypeptide residue that an arbitrary amino acid stood in line in the C-terminal side of this amino acid, H,

A1, A2, A3, A4 and R has the same meaning as the above)

is entirely one aspect of the present invention.

Then, the No. 2 peptide that could solve the above subject is;

a peptide having an affinity to gp120 represented by

Formula(4): H-a1-a2-a3-a4-a5-R

(In the formula,

H means hydrogen,

a1 is tyrosine, arginine, phenylalanine, glycine, tryptophan,

histidine, or asparatic acid reidue,

a2 is arginine, tyrosine, tryptophan, alanine, valine,

glutamine, histidine, or lysine residue,

a3 is lysine, tyrosine, arginine, glutamic acid, methionine, or

tryptophan residue,

a4 is glycine, alanine, valine, leucine, isoleucine, serine,

threonine, methionine, asparagine, glutamine,

histidine, lysine, arginine, phenylalanine, or

tryptophan residue

a5 is glycine, alanine, valine, leucine, isoleucine, serine,

threonine, methionine, asparagine, glutamine,

histidine, lysine, arginine, phenylalanine, tyrosine, or

tryptophan residue,

R is OH derived from carboxyl group or NH₂ derived from acid amide group).

Accordingly, the No.2 peptide in this invention is a 5 amino acid sequence that was constituted by a1, a2, a3, a4 and a5 as described above, and all of the peptide including such amino acid sequences contained by the range of this invention. Thus, a peptide having an affinity to gp120 represented by

Formula(5): a1'-a2-a3-a4-a5-R

(In the formula,

a1' means tyrosine, arginine, phenylalanine, glycine,

tryptophan, histidine, or asparatic acid reidue, or

polypeptide residue that an arbitrary amino acid stood

in the N-terminal side from this amino acid, a2, a3, a4,

a5 and R has the same meaning as above.)

or

Formula(6): H-a1-a2-a3-a4-a5'

(In the formula,

a5' is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tyrosine, or tryptophan residue, or polypeptide residue that an arbitrary amino acid stood in line in the C-terminal side of this amino acid, H, a1, a2, a3, and a4 has the same meaning as above)

is entirely one aspect of the present invention.

In addition, this invention includes a compound which is a macromolecule compound that has a functional group and/or medicine bound to the No.1 or No.2 peptide as mentioned above, or a pharmaceutically acceptable salt thereof.

These peptide compounds or materials including them have an affinity to gp120.

Furthermore, the above peptides or a pharmaceutically acceptable salt thereof, and the composition including pharmaceutically acceptable carrier and/or medicinal bioactivity, are contained in this invention. Also, various aspects, such as; the detection, the diagnosis and the removal to viruses such as HIV by using the above peptide (for example, using the HIV diagnosis or the detection kit contained it, HIV absorbing and removal carrier, and therapy by plasmapheresis) are contained in this invention.

However, the above mentioned "peptide" that is used in this invention contained in the C-terminal peptide is COOH, acid amide and ester etc., and particularly, so long as we do not specify, it contains an aminino acid number (origopeptide) of less than 10, or a polypeptide of more than this.

An amino acid in the above mentioned peptide contains the derivatives that are protected by the protecting functional group. As such amino acid derivatives, it is

marketed the substitution or the modification without exchanging the peptide structure; exchanging the length of the carbon chain etc., or the protecting amino acid derivatives corresponding to various amino acids, but all of these various amino acids can be used in this invention. For example, as tyrosine derivatives, there is 2,6-dichloro-L-tyrosine having chloride in the side chain, p-Nitro-L-phenylalanine that hydroxyl group of p-side in phenylalanine was substituted Nitro group, and 4-chloro-L-phenylalanine that the hydroxyl group was substituted chloride, etc. In addition, as valine derivatives, there are Norvaline: N- α -L-norvaline, or MeVal: N- α -L-valine, etc.

The reason that conventional medicine, such as a vaccine or neutralizing antibody can not be used clinically is that the HIV region the body can recognize as antigen is the V (hypervariable region) region in the envelop gp120, and this is the most problematic. So, the inventors researched a peptide which had a specific affinity to gp120, and as a result, developed a superior peptide and have applied for a patent already (Japanese Patent Application No. H 8-351474 and Japanese Patent Application No. H 8-351475). They developed a peptide which has a high specific affinity to gp120, of the same affinity or more compared to antibody, and which is additionally resistant to heat with a high pressure, such as in autoclave treatment.

However, from research after this, we found that the above-mentioned affinity to gp120 deteriorated by number and there was a kind of amino acid which ranged in it. So, we continued to research further to supply a more stable peptide, and make this invention complete.

In addition to the above, "affinity", this invention shows a specific and tight bond with weak interaction, such as electrostatic interaction, hydrogen bond, Van der Waals

attraction, hydrophobic bond and etc, gathered except a covalent bond.

The peptide in this invention is constituted as mentioned above and is fundamentally shown as 5 amino acid residues which appeared in;

①formula (1): H-A1-A2-A3-A4-A5-R

(in formula, A1, A2, A3, A4, A5 and R the meaning is the same as before) or,

②formula (4): H-a1-a2-a3-a4-a5-R

(in formula, a1, a2, a3, a4, a5 and R the meaning is the same as before)

This peptide has a molecule separate in each and is not(or in peptide), the amino acid sequence mentioned above ①peptide,

formula (2): A1'-A2-A3-A4-A5; or

formula (3): A1-A2-A3-A4-A5'

or above mentioned ②peptide includes the sequence which lined up from N-terminus.

Formula (4): a1'-a2-a3-a4-a5; or

Formula (5): a1 -a2-a3-a4-a5'

(in formula, A1', A2, A3, A4, A5', a1', a2, a3, a4, a5' the meaning is the same as before)

Of course, in, A1'-A2'-A3'-A4'-A5' or a1'-a2'-a3'-a4'-a5' there includes peptides which lined up repeatedly by this order. In brief, this invention includes all of the peptides which consist of 5 amino acid residues and have an affinity to gp120.

The peptide in this invention can be synthesized by conventional methods; For example, the first of this invention is constituted from A1-A2-A3-A4-A5, is synthesized

and the A5 glycine residue, carboxyl of N-protective glycine is bound to some carrier, such as insoluble resin, which has a functional group that can couple to carboxyl. After this, the protected amino acid in each, from A2 to A5, is bound in order by a solid phase synthetic method, and the peptide shown in this invention can be got by reacting the above mentioned insoluble resin and eliminating the protection of the amino acid.

In addition to the above, an end of carboxyl in A5 amino acid residue is free(R, that is to say is equivalent to -OH), or is substituted with acidic amide(R, that is to say is equivalent to -NH₂). Then, an end-carboxyl of A5 with carboxyl of spacer together, bound this carboxyl, binds a synthetic macromolecule, bio-macromolecule, and utilized well macromolecular compound, which has a functional group (as in the postscript). In addition to the above, amino acid used by the above mentioned solid phase synthetic methods is common to L type or D type, but L type is more pleasing.

In the case of the above, the carrier used solid phase synthetic method has carboxyl group of N-protected glycine of C-terminus through the amino group, or if it can bind to this carboxyl group and can eliminate after the binding, it is not limited at all. For example, chloromethyl-resin (chloromethylpolystyrenedivinylbenzene), oxymethyl-resin (oxymethylpolystyrenedivinylbenzene) and others are exemplified. Then, resin of 4-(oxymethyl)phenylacetamidemethyl-resin, 4-(2',4'-Dimethoxyphenyl-aminomethyl)phenoxyacetamidemethyl-resin and etc., benzyloxybenzylalcohol-resin, benzhydramine-resin, insoluble-resin which has amino group, methylbenzhydramine-resin, aminomethylphenoxyethyl-resin, dimethoxybenzhydramine (DMBHA)-resin, and the derivatives are exemplified. In these, benzhydramine-resin, methylbenzhydramine-resin,

aminomethylphenoxymethyl-resin and DMBHA-resin can be get directly amide by cleavage after the binding. Judging from the yield, use of aminomethyl-resin is desirable.

In addition, a spacer which has a functional group binding with carboxyl group and has a carboxyl group are picked up which can transform p-carboxymethylbenzylester-resin to carboxyl group of glycine as in the example.

Moreover, "protecting amino acid" in case of above is meaning protected amino acid with protecting group by conventional method. To synthesize the peptide invented, it is pleasing to use either of the protecting groups shown in the following examples.

In this example, the protecting group of α -amino in amino acid is Boc (t-butoxycarbonyl) or Fmoc (9-fluorenylmethoxycarbonyl); protecting group of ϵ -amino in lysine is Z (benzyloxycarbonyl), Cl \cdot Z(2-chlorobenzyloxycarbonyl), Boc, Npys(3-nitro-2-pyridinesulfonyl); protecting group of hydroxyl group in tyrosine is Bzl(benzyl), Cl₂ \cdot Bzl(2,6-dichlorobenzyle), or t-Bu(*tert.*-butyl) are exemplified, but it uses the peptide synthesis well even if the hydroxyl group of this tyrosine is not protected by the above mentioned protecting group; protecting group of guanidino group in arginine is Tos(tosyl), NO₂(Nitro), Mtr(4-methoxy-2,3,6-trimethylbenzenesulfonyl), or pmc(2,2,5,7,8-pentomethylchloroman-6-sulfonyl); protecting group of carboxyl group in glutamic acid is Bzl ester, t-Bu ester, CHx (cyclohexylester); protecting group of amide group in glutamine is Trt(trityl) is picked up, but it can be used even if glutamine is not protected by this protecting group; the protecting group of indole group in tryptophan is formyl group or Boc, but it can be used even if tryptophan is not protected by this

protecting group. These protecting groups can be used to select the most suitable protecting amino acid according to the condition of the peptide synthesis.

A binding of protecting amino acid can be carried out with the usual condensed-polymerized method, as for example, DCC (N',N'-dicyclohexylcarbodiimide) method (R.B. Merrifield: *Biochemistry*, 3, 1385, 1964), DICDI (N',N'-diisopropylcarbodiimide) method (D. Sarantakis, et al: *Biochem. Biophys. Res. Commun.*, 73, 336, 1976), active-ester method (F. Weygan, et al.: *Z. Naturforsch.*, B, 21, 1141, 1966), mixed or symmetrical acetic anhydride method (D. Yamashiro, et al.: *Proc. Natl. Acad. Sci. USA*, 71, 4945, 1974) carbonyldiimidazole method, DCC-HOBt (1-hydroxybenzotriazole) method (Keonig, W., et al.; *Chem. Ber.*, 103: 788, 1970), diphenylphosphoryl azide method, etc. But particularly, DCC, DCC-HOBt, DICDI-HOBt and symmetric acidic anhydride method are recommended. These condensed -polymerized reactions are usually performed in organic solvent of dichloromethane, dimethylformamide etc. or in their mixture solution.

As in the case above, reagents to eliminate the protecting group of α -amino group, trifluoroacetic acid (TFA)/dichloromethane, HCl/dioxane, piperidine/dimethylformamide (DMF), etc. are used and can be selected freely according to the kind of protecting group. Then, the degree of progress in the condensed reaction on each step of synthesis can be confirmed by the ninhydrin reaction method (E. Kaiser, et al., *Anal. Biochem.*, 34: 595, 1970).

In this way, we can get protected peptide resin which has an amino acid sequence represented with an upper expression, and after this, can get a suitable peptide by elimination of the protecting group from the insoluble resin and amino acid. In the

case using chloromethyl resin as insoluble resin, it is treated by hydrogen fluoride with anisole. Then, in this case used benzyloxybenzylalcohol-resine, benzhydrylamine-resin, and DMBHA resin(Funakoshi, S., J. Chem. Soc., Chem. Commun., 198: 382,1988) , this resin and protecting group can be eliminated at same time by treatment of hydrofluore, TFMSA (Trifluoromethanesulfonicacid), TMSOTF (Trimethylsilyltriflate), TMSBr (Trimethylsilylbromide) and others.

The peptide that is got in this way can be purified by various methods; chromatography (gel, ion-exchange, hydrophobicity, adsorption, reverse phase), electrophoresis and ultrafiltration.

Also included in this invention is a peptide that was substituted on a similar protein(active center or binding domain of antibody, receptor, enzyme and etc.) by a gene recombination method in the case of above peptide. For example, if we produce human anti-gp120 antibody by gene recombinant method, we produce the above-mentioned peptide which is based on the U.S. Patent No. 114632. Namely, this peptide is transduced amino acids of hypervariable cluster in CDR (coplementarity determination region, VH31 to VH35)-1 and CDR-2(VH50 to 52, and/or VH58 to 60), which relates recognition of epitope during the V region in the human immunoglobulin gene (Ohno, S., Mori, N. & Matunaga, T.; Proc. Natl. Acad. Sci. USA. 82, 2945, 1985).

In this way, the peptide of this invention can produce specific binding to, gp120 accordingly to its purpose, substituting the gene recombinant method.

For example, the first peptide in this invention is shown from table 1 to 2 and at same the second peptide is shown from table 3 to 4, respectively. As in the case above,

the table shows an effective agglutinin test and neutralizing activity. Here, No. 24 in Table 1 is equivalent to the first peptide, and also matches the second peptide.

TABLE 1

No.			A1	A2	A3	A4	A5	Agglutinin test	Neutralizing activity
1			Asp	Val	Lys	Ala	Gly	*	
2			Asp	Lys	Val	Ala	Gly	*	
3			Lys	Val	Asp	Ala	Gly	*	
4			Val	Lys	Lys	Ala	Gly		*
5			Asp	Asp	Lys	Ala	Gly		*
6			Lys	Asp	Asp	Ala	Gly	*	
7			Val	Asp	Asp	Ala	Gly	*	
8			Asp	Val	Asp	Ala	Gly	*	
9			Val	Val	Lys	Ala	Gly	*	*
10			Val	Val	Asp	Ala	Gly	*	
11			Lys	Val	Val	Ala	Gly	*	
12			Asp	Asp	Val	Ala	Gly	*	*
13			Asp	Asp	Asp	Ala	Gly		*
14			Val	Lys	Val	Ala	Gly		*
15			Asp	Tyr	Lys	Ala	Ala		*
16			Asp	Phe	Lys	Ala	Gly	*	
17			Asp	Trp	Lys	Ala	Gly	*	
18			Asp	Val	Arg	Ala	Gly	*	
19			Glu	Val	Lys	Ala	Gly	*	
20	Gly	Gly	Asp	Val	Lys	Ala	Gly	*	
21		Gly	Asp	Val	Lys	Ala	Gly	*	
22			Val	Ile	Asp	Ala	Gly	*	
23			Val	Leu	Asp	Ala	Gly	*	
24			Gly	Val	Lys	Ala	Gly	*	
25			Asp	Val	Lys	Trp	Ala	*	
26			Asp	Val	Lys	Gly	Lys	*	
27			Asp	Val	Lys	Gly	Trp	*	

TABLE 2

No.			A1	A2	A3	A4	A5	agglutinin test	neutralizing activity
28			Asp	Val	Ala	Ala	Gly	*	
29			Asp	Val	Lys	Gly	Leu	*	
30			Asp	Val	Lys	Gly	Pro	*	
31			Asp	Val	Lys	Ala	Val	*	
32			Asp	Val	Lys	Ala	Ile	*	
33			Asp	Val	Lys	Ala	Ser	*	
34			Asp	Val	Lys	Ala	Thr	*	
35			Asp	Val	Lys	Ala	Met	*	
36			Asp	Val	Lys	Ala	Gln	*	
37			Asp	Val	Lys	Ala	Asn	*	
38			Asp	Val	Lys	Ala	His	*	
39			Asp	Val	Lys	Ala	Arg	*	
40			Asp	Val	Lys	Ala	Phe	*	

TABLE 3

No.			A1	A2	A3	A4	A5	Agglutinin test	Neutralizing activity
1			Phe	Tyr	Arg	Lys	Ala	*	*
2			Tyr	Arg	Arg	Ala	Ala		*
3			Trp	Trp	Glu	Ala	Ala	*	*
4			Tyr	Gln	Glu	Ala	Ala	*	
5			Gly	Tyr	Tyr	Lys	Ala	*	*
6			Trp	Trp	Lys	Ala	Ala	*	*
7			Tyr	Tyr	Arg	Ala	Ala		*
8			Phe	Arg	Lys	Ala	Ala		*
9			Tyr	Tyr	Lys	Lys	Ala	*	*
10			Tyr	Tyr	Lys	Leu	Leu		*
11			Tyr	Arg	Lys	Ala	Ala	*	*
12			Tyr	Tyr	Lys	Ala	Ala	*	*
13			Arg	Tyr	Lys	Ala	Ala	*	*
14			Phe	Tyr	Arg	Ala	Ala		*
15			Tyr	Ala	Lys	Ala	Ala	*	*
16			Tyr	Tyr	Glu	Ala	Ala	*	
17			Tyr	Trp	Lys	Ala	Ala	*	
18		Gly	Tyr	Tyr	Lys	Ala	Ala	*	
19			Trp	Tyr	Lys	Ala	Ala	*	
20			Tyr	Gln	Lys	Ala	Ala	*	
21			His	Tyr	Lys	Ala	Ala	*	
22			Tyr	Arg	Tyr	Ala	Ala	*	*
23			Tyr	Tyr	Met	Ala	Ala		*
24			Tyr	Val	Lys	Ala	Ala		*
25		Gly	Tyr	Ala	Tyr	Arg	Lys	*	
26			Arg	Arg	Trp	Ala	Tyr	*	*
27		Arg	Tyr	Tyr	Lys	Ala	Ala	*	

TABLE 4

No.			A1	A2	A3	A4	A5	Agglutinin test	Neutralizing activity
28			Tyr	Lys	Lys	Ala	Ala	*	
29			Tyr	His	Lys	Ala	Ala	*	*
30			Asp	Tyr	Lys	Ala	Ala	*	
31			Tyr	Tyr	Lys	Trp	Ala	*	
32			Tyr	Tyr	Lys	Gly	Ala	*	
33			Tyr	Tyr	Lys	Ala	Gly	*	
34			Tyr	Tyr	Lys	Lys	Ala	*	
35			Tyr	Tyr	Lys	Val	Ala	*	
36			Tyr	Tyr	Lys	Ile	Ala	*	
37			Tyr	Tyr	Lys	Ser	Ala	*	
38			Tyr	Tyr	Lys	Thr	Ala	*	
39			Tyr	Tyr	Lys	Met	Ala	*	
40			Tyr	Tyr	Lys	Gln	Ala	*	
41			Tyr	Tyr	Lys	Asn	Ala	*	
42			Tyr	Tyr	Lys	His	Ala	*	
43			Tyr	Tyr	Lys	Phe	Ala	*	
44			Tyr	Tyr	Lys	Trp	Ala	*	
45			Tyr	Tyr	Lys	Arg	Ala	*	
46			Tyr	Tyr	Lys	Ala	Val	*	
47			Tyr	Tyr	Lys	Ala	Ile	*	
48			Tyr	Tyr	Lys	Ala	Ser	*	
49			Tyr	Tyr	Lys	Ala	Thr	*	
50			Tyr	Tyr	Lys	Ala	Met	*	
51			Tyr	Tyr	Lys	Ala	Gln	*	
52			Tyr	Tyr	Lys	Ala	Asn	*	
53			Tyr	Tyr	Lys	Ala	His	*	
54			Tyr	Tyr	Lys	Ala	Phe	*	
55			Tyr	Tyr	Lys	Ala	Trp	*	
56			Tyr	Tyr	Lys	Ala	Arg	*	

A sign of each amino acid formula shows the amino acid residue by the internationally approved characters, the details are as follows:

Tyr: Tyrosine

Lys: Lysine

Trp: Tryptophan

Arg: Arginine

Glu: Glutamic acid

Gln: Glutamine

His: Histidine

Ala: Alanine

Phe: Phenylalanin

Gly: Glycine

Met: Methionine

Asp: Asparatic acid

Asn: Asparagine

Val: Valine

Ser: Serine

Cys Cystine

Thr: Threonine

Ile: Isoleucine

Leu: Leucine

Pro: Proline

A peptide having such an amino acid sequence shows a superior affinity to gp120, and can be utilized effectively as an anti-HIV medicine by taking a form of chemical compound or composition shown as follows.

A compound of this invention is matter that binds a high molecular chemical compound and/or medicinal activator functional group, and this invention includes the salts to be admitted as medicine.

For example, as pharmaceutically acceptable salts here, following intoxicant salts in

common use is put up.

① As salts with bases such as inorganic bases, there are alkali metal salt (for example, sodium salt and potassium salt), alkaline earth metal salt (for example, calcium salt, magnesium salt) and ammonium salt; ② as salts with such as organic bases, there is salts of organic amines (for example, triethylamine, pyridine, picoline, ethanolamine, triethanolamine, dicyclohexylamine, N,N'-dibenzylethylenediamines), etc; ③ as salts with acids such as inorganic acids, there are hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid; ④ as salts with acids such as organic acids, there are organic carboxylic acid (for example, acetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid and salicylic acid), organic sulfonic acid (for example, methanesulfonic acid, p-toluenesulfonic acid), glyconic acid (glucuronic acid, galactonic acid, gluconic acid, ascorbic acid , and others).

Then, "macromolecule compound having functional group" used on this invention is not particularly limited if it can bind the peptide of this invention, for example, the following are listed.

(1) Synthetic polymer

It is selected voluntarily among the inside of linear, branched and cyclic, as polymer in case of above. For example, it can be used as an insoluble solid phase carrier of amino acidic homopolymer of polylysine and polyglutamic acids, or cyclic polyamine, cyclodextrin, cyclic peptide and then polystyrene, polypropylene, nylon, silica-gel, polyethyleneglycol, cellulose, polyacrylamide, and others.

09757556 : 070204

A branched polymer in these is higher than the usual homopolymer on content of functional groups per unit because of divergence at one part in each. For example, it seems to be the lysine core indicated by Denkewalter and is a polymer that is based on the same molecular chain, more than two, derived from a core molecule having at least two or more having functional groups U.S. Patent No. 4,289,872; or it is a starburst dendrimer that the polymer size is regulated closely because the same molecule reacts continuously, proposed by Tomalia and et al; or it is the molecule that size was formed irregular , by which the same or different molecule reacts to discontinuity. In addition, a homo-/branched-polymer as in the case of above does not always to need a carrier which has enough size, and it has a monomer of around 3 that does not usually seem to be recognized as a core, and it is not limited by the size or introduction number. However, in the case when it is introduced to numerous peptide formulas, use of divergence numerical polymer is recommended but even if it is anything polymer. When the peptide of this invention is bound (to the above mentioned polymer) it is possible that it is synthesized and just grown directly/indirectly from the branched functional group, or that it is conjugated directly/indirectly from the functional group of the polymer to a new separate synthetic peptide.

Moreover, for binding cyclic polymer of cyclic polyamine, cyclodextrin, and cyclic peptides, it is possible to synthesis directly and make the peptide of upper expression from the same functional group, or to bind directly/indirectly to a new synthetic peptide separately or to a functional group of the cyclic polymer. Then, to bind the insoluble carrier of silica gel etc., after it is introduced to the same functional group carrier in advance, it can be synthesized and just grow directly peptide of upper expression from

the functional group, or conjugate directly/indirectly from the functional group of insoluble carrier to the new synthetic peptide separately. In addition, the particular size and shape of the carrier having this same functional group is not limited, and selection and utilization of: spherical, hollow fibrous, fibrous shapes can be made according to their purpose and then, it is not limited at all by size and shape and can be introduced to several functional groups.

(2) Biopolymer

As above mentioned biopolymer, there are, for example, linear polymer like polysaccharide, such as heparin, hyaluronic acid, chitosan, chitin, etc.; proteins of proteoglycans, peptide hormone; gelatin, albumin, antibody, and antibody's fragments, etc.

The size of linear polymer in these can be an appropriately selected, according to the purpose of use, and includes some monomer of around 3 that does not usually seems to be recognized as a polymer, but is not limited at all by the size or number of functional groups. For binding a peptide of upper expression to this linear polymer, you may directly synthesis and just grow it from the same functional group, or may directly/indirectly conjugate a new synthetic peptide separately to the functional group of the linear polymer.

In addition, when peptide hormone and protein is bound to the polymer, it is possible that either end of the peptide of upper expression is bound to cysteine and do disulfide binding with the residue of cysteine in the above mentioned peptide hormone/protein, or

is conjugated directly/indirectly to the functional group in the above mentioned peptide hormone/protein with functional group peptide in upper expression. In this way, we can freely select these binding methods according to the purpose of use, and also it is the same even if the kind and number of peptide shown by upper expression is transduced.

Moreover, an active medicine used by this invention is, for example, AZT of nucleoside derivative known as HIV inhibitor, 3,4-Duhydroxy-2,5-di[N-methyl-(2-pyridylmethyl) carbamoyl]valylamino]-1,6-diphenylhexanes known as protease inhibitor against HIV. These active medicines can be used to produce specific medicines against HIV. Accordingly, such a medicine is useful as the treatment medicine that can specifically treat HIV.

Furthermore, the range of this invention also includes a composition that contains a salt and a carrier pharmaceutically permitted as medicine and /or active medicine.

As mentioned above [the pharmaceutically permitted carrier] can select the appropriate use of an excipient (disintegrator, lubricant, expander etc.), color additives, preservative, stabilizer and other carriers in common use. The following have definitely been shown crystal cellulose, calcium carmelose, sodium carmelose, hydroxypropylcellulose, hydroxypropylmethylcellulose, ethylcellulose, magnesium stearate, talc, light anhydrouse silicic acid, food color agents, essential oil, etc.

Based on the following enforcement examples, we will describe the details of this invention. However, the following enforcement example does not limit this invention, the technological range of this invention includes all enforcing changes within the range

that does not deviate from the purpose of the postscript.

Synthesis 1: Compound which was bound polyethylene glycol
with the peptide in this invention

After induction of carboxyl group by which was reacted anhydride succinic acid against a hydroxyl group of polyethylene glycol (MW. 20,000), it is reacted MBS (m-maleimide benzoyl-N-hydroxysuccinimide), and we synthesized maleimide polyethylene glycol.

Then, we synthesized peptide-polyethylene glycol binding compound, by which performed peptide binding to peptide induced cysteine against C-terminal of No.1 peptide shown by Table 1 mentioned above. After suspending this compound in phosphate buffer solution, it was purified by gel chromatography and affinity chromatography by gp120 conjugated carrier, and then, polyethylene glycol binding compound to the peptide was synthesized.

Synthesis 2: Compound which was bound cyclodextrin
with the peptide in this invention

After induced carboxyl group by which was reacted anhydride succinic acid against a hydroxyl group of α -cyclodextrin, it was reacted MBS(m-maleimide benzoyl-N-hydroxysuccineimide), and we synthesized maleimide cyclodextrin.

On the other hand, after synthesized a peptide which was performed peptide binding

to C-terminus of cysteine of No.12 peptide on Table 3 mentioned above, it reacted to the above maleimide cyclodextrin, and we synthesized a cyclic compound that cyclodextrin binding compound to the peptide.

Synthesis 3: Compound (1) which was bound branched polymer
with the peptide in this invention

Branched polymer binding compound was synthesized by extending No.1 peptide on the above Table 1 from N-end amino acid MAPs (Multiple antigenic peptide). After the compound was suspended in phosphate buffer, it was purified by gel chromatography and affinity chromatography by gp120 conjugated carrier, and then, we synthesized branched polymer binding compound to the peptide in this invention (1).

Synthesis 4: Compound (2) which was bound branched polymer
with the peptide in this invention

Branched polymer binding compound was synthesized by extending No.12 peptide on the above Table 3 from N-end amino acid MAPs (Multiple antigenic peptide). After the compound was suspended in phosphate buffer, it was purified by through gel chromatography and affinity chromatography by gp120 conjugated carrier, and we synthesized branched polymer binding compound to the peptide in this invention (2).

Synthesis 5: Compound which was bound AZT

with the peptide in this invention

After preparing mixed anhydride to react isobutyl chloroformate with bromoacetic acid, we synthesized bromoacetylestel-AZT by esterification, of the hydroxyl group of AZT. On the other hand, after synthesizing by solid phase method binding the peptide that cysteine was bound C-end amino acid of No.12 peptide on the above Table 3, it was reacted with the above bromoacethylestel-AZT, and then we obtained AZT binding compound, which is a cross-linking with this peptide.

Synthesis 6: Compound which was bound inactive alkaline

phosphatase with the peptide in this invention

We synthesized maleimide alkaline phosphatase, by which inactive alkaline phosphatase (Alp) was reacted MBS (maleimide benzoile-N-hydroxysuccinimide).

Then, No.8 peptide on the above Table 3 induced cysteine was bound with the maleimide group, and we synthesized inactive alkaline phosphatase binding compound. An inactive form of alkaline phosphatase was identified by the confirmation that there was no production of p-nitrophenol when using p-nitrylphenyl phosphate as a substrate.

Synthesis 7: An absorbing and removing carrier (1)

which was bound Sephadex 6MB with the peptide in this invention

No.1 peptide on the above Table 1 was bonded covalently to Sephadex 6MB by intermediating an activated spacer beforehand, and peptide/Sepharose 6MB(1 μ mol of gp120/ml in bed volume) was prepared. Unreactive peptide was centrifuged at room temperature for 10 minutes(12,000 rpm) by using phosphate buffer and was removed by repeating the absorbing and removing the preparation to the supernatant.

Synthesis 8: An absorbing and removing carrier (2)

which was bound Sephadex 6MB with the peptide in this invention

No.12 peptide on the above Table 3 was done covalent bond to Sephadex 6MB by intermediating an activated spacer beforehand, and peptide/Sepharose 6MB(1 μ mol of gp120/ml in bed volume) was prepared. Unreactive peptide was centrifuged at room temperature for 10 minutes(12,000 rpm) by using phosphate buffer and was removed by repeating the absorbing and removing the preparation to the supernatant.

Synthesis 9: an absorbing and removing carrier

which was bound Sephadex 4B with the peptide in this invention

No.12 peptide on the above Table 3 was done covalent bond to Sephadex 4B by intermediating an activated spacer beforehand, and the peptide/Sepharose 4B(1 μ mol of

gp120/ml in bed volume) was prepared. Unreactive peptide was centrifuged at room temperature for 10 minutes(12,000 rpm) by using phosphate buffer and was removed by repeating the absorbing and removing the preparation to the supernatant.

Synthesis 10: an absorbing and removing carrier

which was bound cellulose type carrier with the peptide
in this invention

No.12 peptide on the above Table 3 was done covalent bond to a peroxy-cellulose carrier, and it was prepared by washing carefully with sodium hydrogen carbonate buffer(pH8) and phosphate buffer(pH4) after blocking by glycine, We prepared an absorbing and removing carrier which was bound cellulose series carrier with the peptide.

EXAMPLE 1: investigation of neutralizing activity

In this example, we investigated neutralizing activity of HIV-1 using various peptides, shown in Tables 5 and 6.

We added separately 50 μ L of the above peptide ; 50 μ L of 200TCID⁵⁰ of HTLV-III_B (laboratory strain) and KK-1(freshly isolated HIV, Ohtake et al. Kansenshou(Japanese), 64,1284-1294,1990) in each; and 50 μ L of the above peptide precisely diluted by 2 times step-by-step in 96-well microplate, and mixed. Then, we used AZT as a positive control.

After incubation for 30 minutes at 37°C, 100 μ L of MT-4 cell suspension of 3×10^4 cells was added and incubated for 6 days at 37°C under 98% of humidity and 5% of CO₂. After the incubation, cell plasmodium effect (CPE) by HIV-1 proliferation, namely when a medicine was added with dilution step-by-step and infection cells gathered and became a state to form an island(focus form), was judged as an intensity of neutralizing activity(content to inhibit infection) on a pre-stage of this diluted magnification. These results are shown jointly in Tables 5 and 6.

TABLE 5

No.	Amino acid sequence					HIV neutralizing activity(μ g/ml)	
	A1	A2	A3	A4	A5	HTLV-III _B	KK-1
1	Val	Lys	Lys	Ala	Gly	Nglu	15.6
2	Asp	Asp	Lys	Ala	Gly	62.5	NE
3	Val	Val	Lys	Ala	Gly	31.3	NE
4	Asp	Asp	Val	Ala	Gly	500	NE
5	Asp	Asp	Asp	Ala	Gly	1,000	1,000
6	Val	Lys	Val	Ala	Gly	125	NE
7	Asp	Tyr	Lys	Ala	Ala	31.3	125

TABLE 6

No.	Amino acid sequence					Anti-HIV neutralizing activity(μ g/ml)	
	a1	a2	a3	a4	a5	HTLV-III _B	KK-1
1	Phe	Tyr	Arg	Lys	Ala	250	125
2	Tyr	Arg	Arg	Ala	Ala	250	125
3	Trp	Trp	Glu	Ala	Ala	250	NE
4	Gly	Tyr	Tyr	Lys	Ala	31.3	125
5	Tyr	Tyr	Arg	Ala	Ala	250	250
6	Phe	Arg	Lys	Ala	Ala	125	125
7	Tyr	Tyr	Lys	Lys	Ala	312.5	312.5
8	Tyr	Tyr	Lys	Leu	Leu	31.3	62.5
9	Tyr	Arg	Lys	Ala	Ala	312.5	156.3
10	Tyr	Tyr	Lys	Ala	Ala	78.1	39.1
11	Arg	Tyr	Lys	Ala	Ala	62.5	31.25
12	Phe	Tyr	Arg	Ala	Ala	NE	250-125
13	Tyr	Ala	Lys	Ala	Ala	500	NE
14	His	Tyr	Lys	Ala	Ala	NE	500
15	Tyr	Arg	Tyr	Ala	Ala	31.25	31.25
16	Tyr	Tyr	Met	Ala	Ala	NE	125
17	Tyr	Val	Lys	Ala	Ala	NE	250
18	Arg	Arg	Trp	Ala	Tyr	39.1	39.1
19	Tyr	His	Lys	Ala	Ala	500	500

Note) HTLV-III_B; Laboratory strain

KK-1; Freshly isolated strain from domestic HIV patients

NE; No effect

As is clear from the result of Tables 5 and 6, neither peptide which was not satisfied with a matter of this invention showed neutralization activity to HIV-1, while the peptides which satisfied it showed superior activity. Then, a peptide of this invention shown in Table 5 presents No.1 peptide of this invention, and the peptide of Table 6 shows the No.2, in each. In addition to the laboratory strain, when this invented peptide showed superior activity to the freshly isolated strain, this suggested it would be

extremely useful at a practical level beyond the laboratory.

EXAMPLE 2: agglutinin test

In this example, we used the peptide shown in Table 7-10, and evaluated it by an agglutinin test for the affinity to gp120.

After mixing equally both a suspension of 1% activation latex beads (Polyscience Inc., particle size is 0.2mm) and avidin(10mg/mL). we incubated for 1hour at 37°C. After the incubation, we added bovine serum albumin(BSA, 1mg/mL) in it and carried out blocking of the reactive site for 30 minutes at 37°C. Then, after removing the binding reagent by centrifuging repeatedly, biotinylated peptide (10mg/mL in phosphate buffer, pH7.5) was added to each, and anti-gp120 agglutinin reagent was prepared by incubation for 1 hour at 37°C.

As a positive control, we used colloidal gold conjugated by recombinant gp120 that was expressed in baculo virus(Immunodiagnostics Inc., particle size is 30nm), while as a negative control, we used this recombinant gp120 that was dissolved in phosphate buffer.

20 μ of the above agglutinin reagent and positive control were added and mixed on a test disk separately, we investigated it with the naked eye after standing for 10 minutes. The results are shown jointly in Tables 7 to 10. When we used a negative control instead of a positive control in this enforcement example, we confirmed that the agglutination was not observed.

TABLE 7

No.	Amino acid sequence							Agglutinin test
			A1	A2	A3	A4	A5	gp120/C.G.
1			Asp	Val	Lys	Ala	Gly	+++
2			Asp	Lys	Val	Ala	Gly	+
3			Lys	Val	Asp	Ala	Gly	+++
4			Asp	Asp	Lys	Ala	Gly	+
5			Lys	Asp	Asp	Ala	Gly	++
6			Val	Asp	Asp	Ala	Gly	++
7			Asp	Val	Asp	Ala	Gly	+
8			Val	Val	Lys	Ala	Gly	+
9			Val	Val	Asp	Ala	Gly	+++
10			Lys	Val	Val	Ala	Gly	+
11			Asp	Tyr	Lys	Ala	Ala	+
12			Asp	Phe	Lys	Ala	Gly	++
13			Asp	Trp	Lys	Ala	Gly	++
14			Asp	Val	Arg	Ala	Gly	+
15			Glu	Val	Lys	Ala	Gly	++
16	Gly	Gly	Asp	Val	Lys	Ala	Gly	+++
17		Gly	Asp	Val	Lys	Ala	Gly	++
18			Val	Ile	Asp	Ala	Gly	+
19			Val	Leu	Asp	Ala	Gly	+
20			Gly	Val	Lys	Ala	Gly	+
21			Asn	Val	Lys	Ala	Gly	+++
22			Asp	Val	Lys	Trp	Ala	+
23			Asp	Val	Lys	Gly	Lys	+
24			Asp	Val	Lys	Gly	Trp	+
25			Asp	Val	Lys	Gly	Leu	+
26			Asp	Val	Lys	Gly	Pro	+

TABLE 8

No.	Amino acid sequence							Agglutinin test
			A1	A2	A3	A4	A5	gp120/C.G.
27			Asp	Val	Lys	Ala	Val	+
28			Asp	Val	Lys	Ala	Ile	+
29			Asp	Val	Lys	Ala	Ser	+
30			Asp	Val	Lys	Ala	Thr	+
31			Asp	Val	Lys	Ala	Met	+
32			Asp	Val	Lys	Ala	Gln	+
33			Asp	Val	Lys	Ala	Asn	+
34			Asp	Val	Lys	Ala	His	+
35			Asp	Val	Lys	Ala	Arg	+
36			Asp	Val	Lys	Ala	Phe	+

TABLE 9

No.	Amino acid sequence						Agglutinin test gp120/C.G.
		a1	a2	a3	a4	a5	
1		Phe	Tyr	Arg	Lys	Ala	+
2		Trp	Trp	Glu	Ala	Ala	+
3		Tyr	Gln	Glu	Ala	Ala	+
4		Gly	Tyr	Tyr	Lys	Ala	+
5		Trp	Trp	Lys	Ala	Ala	+++
6		Tyr	Tyr	Lys	Lys	Ala	+
7		Tyr	Arg	Lys	Ala	Ala	+
8		Tyr	Tyr	Lys	Ala	Ala	+
9		Arg	Tyr	Lys	Ala	Ala	+
10		Tyr	Ala	Lys	Ala	Ala	+
11		Tyr	Tyr	Glu	Ala	Ala	+
12		Tyr	Trp	Lys	Ala	Ala	+
13	Gly	Tyr	Tyr	Lys	Ala	Ala	+
14		Trp	Tyr	Lys	Ala	Ala	+
15		Tyr	Gln	Lys	Ala	Ala	++
16		His	Tyr	Lys	Ala	Ala	+
17		Tyr	Arg	Tyr	Ala	Ala	++
18	Gly	Tyr	Ala	Tyr	Arg	Lys	+
19		Arg	Arg	Trp	Ala	Tyr	+
20	Arg	Tyr	Tyr	Lys	Ala	Ala	+
21		Tyr	Lys	Lys	Ala	Ala	+
22		Tyr	His	Lys	Ala	Ala	+
23		Asp	Tyr	Lys	Ala	Ala	+
24		Tyr	Tyr	Lys	Trp	Ala	+
25		Tyr	Tyr	Lys	Gly	Ala	+
26		Tyr	Tyr	Lys	Ala	Gly	+

TABLE 10

No.	Amino acid sequence						Agglutinin test
	a1	a2	A3	a4	a5		gp120/C.G.
27	Tyr	Tyr	Lys	Lys	Ala		+
28	Tyr	Tyr	Lys	Val	Ala		+
29	Tyr	Tyr	Lys	Ile	Ala		+
30	Tyr	Tyr	Lys	Ser	Ala		+
31	Tyr	Tyr	Lys	Thr	Ala		+
32	Tyr	Tyr	Lys	Met	Ala		+
33	Tyr	Tyr	Lys	Gln	Ala		+
34	Tyr	Tyr	Lys	Asn	Ala		+
35	Tyr	Tyr	Lys	His	Ala		+
36	Tyr	Tyr	Lys	Phe	Ala		+
37	Tyr	Tyr	Lys	Trp	Ala		+
38	Tyr	Tyr	Lys	Arg	Ala		+
39	Tyr	Tyr	Lys	Ala	Val		+
40	Tyr	Tyr	Lys	Ala	Ile		+
41	Tyr	Tyr	Lys	Ala	Ser		+
42	Tyr	Tyr	Lys	Ala	Thr		+
43	Tyr	Tyr	Lys	Ala	Met		+
44	Tyr	Tyr	Lys	Ala	Gln		+
45	Tyr	Tyr	Lys	Ala	Asn		+
46	Tyr	Tyr	Lys	Ala	His		+
47	Tyr	Tyr	Lys	Ala	Phe		+
48	Tyr	Tyr	Lys	Ala	Trp		+
49	Tyr	Tyr	Lys	Ala	Arg		+

Note) gp120/C.G.; gp120 conjugated colloidal gold

Degree of agglutination: +++ > ++ > +(agglutination), -(no agglutination)

From the results in Tables 7-10, we can confirm that each peptide shown in this invention has a superior affinity to gp120. The peptide of this invention is shown in Tables 7 and 8 is the No.1 peptide in this invention, and it shown in Tables 9 and 10 is the No.2 peptide of it.

EXAMPLE 3: Effect of A4 and A5

in this invention on the agglutinin test

To examine the effect of A4 and A5 amino acid on the agglutinin test, the chain length of the No.1 peptide in TABLE 7 was changed. The agglutination was measured the same as in 2. These results are shown jointly in TABLE 11. Face note, \pm means "agglutination in trace degree".

TABLE 11

No.	Amino acid sequence					Agglutinin test
	A1	A2	A3	A4	A5	gp120/C.G.
1	Asp	Val	Lys	Ala	Gly	+++
2	Asp	Val	Lys	Ala	-	+
3	Asp	Val	Lys	-	-	\pm

From TABLE 11, both No.3 with only 3 amino acids (there are no a4 and a5 amino acids) and in No.2 with only 4 amino acids (there are no a5 amino acids) neutralizing activity decreased remarkably composed to No.1 with five amino acids. Namely, by the amino acid numerical decrease, the neutralizing activity has a tendency to fall, and particularly No.3, having three amino acids missing in all.

EXAMPLE 4: Effect of a4 and a5

in this invention on neutralizing activity

To examine the effect of a4 and a5 amino acids on neutralizing activity, the chain length of No.8 in table 9 were changed. The activity was measured the same as in

example 1. Their results are shown in TABLE12. Face note, NE means “NO EFFECT”.

TABLE 12

No.	Amino acid sequence					Anti-HIV neutralizing activity (μ g/ml)	
	a1	a2	A3	a4	a5	HTLV-IIIB	KK-1
1	Tyr	Tyr	Lys	Ala	Ala	78.1	39.1
2	Tyr	Tyr	Lys	Ala	-	NE	250
3	Tyr	Tyr	Lys	-	-	NE	NE

From TABLE12, both No.3 with only 3 amino acids(there is not a4 and a5 amino acid) and No.2 with only 4 amino acids(there is not a5 amino acids) neutralizing activity decreased remarkably compared to No.1 with five amino acids. Namely, by amino acid numerical decrease, the neutraizing activity has a tendency to fall, and particularly, No.3 having three amino acids missing in all.

EXAMPLE 5: Effect of a4 and a5

in this invention on neutralizing activity

To examine the effect of a4 and a5 on neutralizing activity, No.1 peptide in TABLE 13 was used as a positive control, while we used a peptide(No.2) that kind of a4 amino acids was changed to leucine, hydrophobic amino acid of same as alanine , or a peptide(No.3) that was changed to proline. Then, we examined the effect to neutralizing activity as in EXAMPLE 1. The results are shown jointly in TABLE 13.

TABLE 13

No.	Amino acid sequence					Anti-HIV neutralizing activity (μ g/ml)	
	a1	a2	a3	a4	a5	HTLV-III _B	KK-1
1	Tyr	Tyr	Lys	Ala	Ala	78.1	39.1
2	Tyr	Tyr	Lys	Leu	Leu	31.3	62.5
3	Tyr	Tyr	Lys	Pro	Pro	NE	NE

From TABLE 13, the kinds of a4 and a5 amino acids differed from the amino acid that was identified by this invention on No.1, the neutralizing activity decreased or disappeared. The results suggest that these kinds of a4 and a5 amino acid have an important effect on the expression of the activity.

EXAMPLE 6: Effect of A4 and A5

in this invention on agglutinin test

We examined the effect of A4 and A5 on agglutinin test as shown in TABLE 14. The No.1 peptide was used as a positive control, while we used a peptide (No.2) that kind of A4 amino acids was changed to leucine, hydrophobic amino acid of same as alanine, or a peptide(No.3) that was changed to aspartic acid, acidic amino acid; similarly, the peptide(No.4) was changed to proline, and the peptide(No.5) was changed to glutamic acid. Then, we examined the effects on neutralizing activity the same as in EXAMPLE 2. The results are shown jointly in table 14. Face note, \pm means "an agglutinin in trace degree".

TABLE 14

No.	Amino acid sequence					Agglutinin test
	A1	A2	A3	A4	A5	Colloidal gold conjugated gp120
1	Asp	Val	Lys	Ala	Gly	+++
2	Asp	Val	Lys	Pro	Gly	-
3	Asp	Val	Lys	Asp	Gly	-
4	Asp	Val	Lys	Ala	Pro	-
5	Asp	Val	Lys	Ala	Glu	±

From TABLE 14, when a kind of A4 and A5 amino acid on No.1 were exchanged to a different amino acid, the agglutinin was negative, or decreased to a trace degree. These results suggest that the kind of A4 and A5 amino acids have important effects on agglutinin test.

EXAMPLE 7: Effect of macromolecularization

on neutralizing activity

We examined the effect of the peptide binding macromolecule on neutralizing activity. An inactive alkaline phosphatase (Alp) was used as the macromolecule, and it was bound to the peptide that was prepared in SYNTHESIS 6, the same as in EXAMPLE 1. No.8 peptide was used as a positive control on TABLE 3, while unbound inactive alkaline phosphatase was used as negative control. These results are shown jointly in TABLE 15. Face note, NE means "negative".

TABLE 15

		Anti-HIV neutralizing activity(μ g/ml)	
		HTLV-III _B	KK-1
Macro-molecule	Inactive Alp binding peptide	125-250	62.5
Positive control	peptide	125	125
Negative control	inactive Alp	NE	NE

From TABLE 15, when the peptide in this invention bound to protein already known and grew up to a macromolecule, the solubility improved and the neutralization activity increased too.

EXAMPLE 8: the antibody-like effect

by doing induction of the peptide more than once

After the peptide binding α -cyclodextrin prepared in SYNTHESIS 2 in human serum was suspended, we examined whether we could detect with a commercial diagnosis medicine kit for HIV(Dinabot Co., 「HIV-1/HIV-2 EIA」). The judgment principle of this HIV diagnosis medicine kit was that it detects an anti-HIV antibody formed in patient serum, and particularly, it's good point is that it can detect IgM antibody appearing at an early stage of HIV infection. The result is shown in Fig. 1.

As is shown in Fig. 1, the above diagnosis medicine, which detects only anti-HIV antibodies present in HIV patient's serum, can detect depending on the content peptide induced binding to α -cyclodextrin. From this result, the peptide in this invention has an affinity to HIV, and it clearly showed an antibody like effect when induction of the peptide was done more than once.

EXAMPLE 9: the affinity of the peptide to gp120(1)

The peptide bound to Sephadex 6MB that was prepared in SYNTHESIS 7 was added to the various kinds of density prepared horseradish peroxidase (HRP) labeled HIV-1-gp120(Immuno Diagnosis Co.) and enzyme unlabeled HIV-1-gp120 previously in each and constant disassociation(kd) of peptide in this invention calculated by drawing up a Schacherd Plot we calculated was $k_d = 2.14 \times 10^{-10} \text{M}$.

From this result, it is clear that the peptide in this invention has an affinity of equal to, or greater than the antibody.

EXAMPLE 10: an affinity of the peptide to gp120(2)

The peptide binding Sephadex 4B that was prepared in SYNTHESIS 7 was added to the various kinds of density prepared horseradish peroxidase (HRP) and labeled HIV-1-gp120(Immuno Diagnosis Co.) and enzyme unlabeled HIV-1-gp120 previously in each and constant disassociation(kd) of the peptide in this invention calculated by drawing up a Schacherd Plot we calculated was $k_d = 4.97 \times 10^{-10} \text{M}$.

From this result, it is clear that the peptide in this invention has an affinity of equal to, or greater than the antibody.

EXAMPLE 11: a number of recognition site

of the peptide to gp120(1)

To confirm the specificity of the peptide in this invention, we made "peptide conjugated latex beads" that labeled peptide of No.1 in TABLE 1 and No.6 in TABLE 3 on red colored latex beads(Polyscience Co., 200nm in diameter). When pseudo HIV-1 solution(gp120 conjugated colloidal gold) was added in 200 μ l of this latex beads solution, red agglutination that could be observed by the naked eye promptly and easily appeared. When the unlabelled gp120 solution(1 μ g protein /ml) that was not conjugated with colloidal gold was added to it, it did not agglutinate at all. For this reason, we inferred that the peptide in this invention bound only to the location of one site in gp120. The results are shown in TABLE 16.

TABLE 16

Agglutinin test	Colloidal gold conjugated gp120 protein contents(1 μ g/ml)	gp120 protein contents(1 μ g/ml)
No.1 in Table 1	Presence	Absence
No.6 in Table 3	Presence	Absence

EXAMPLE 12: the specificity test

By using "peptide conjugated latex beads", latex agglutination test medicine of 2 kinds of peptide (No. 1 in Table and No. 6 in Table 3) that were prepared with Enforcement example 7, we examined whether nonspecific binding existed. The virus that was in use in this enforcement example was serum, laboratory strain and a freshly isolated strain that was gathered from patients of hepatitis C or B at final stage. Then, we used virus lysate that conjugated colloidal gold as previously. Titer or number (No.)

used virus and presence of agglutination are shown in TABLE 17.

TABLE 17

No.	Sample/Virus	Titer or No.	Presence of agglutinin	
			Table 1 No.1	Table 3 No.6
1	HIV-1 IIB	1.0×10^5 TCID ₅₀	+	+
2	HIV-1 Lav 1	1.0×10^5 TCID ₅₀	+	+
3	HIV-1 kk-1	$1.0 \times 10^{4.5}$ TCID ₅₀	+	+
4	HIV-2 Lav2	1.0×10^6 TCID ₅₀	-	-
5	Serum of HCV patients	indistinct	-	-
6	Serum of HBV patients	indistinct	-	-
7	Hepatitis B surface antigen(HbsAg)	1.6×10^5 units	-	-
8	Varicella Zoster valirus	9.5×10^5 units	-	-
9	Argubella Zoster valirus(VZV)	4.9×10^5 units	-	-
10	HTLV-1 virul lysate	1.1×10^5 units	-	-
11	human cytomegalovirus(HCMV)	5.5×10^5 units	-	-
12	Epstein-Barr virus(EB virus)	9.9×10^5 units	-	-

From TABLE 17, it is clear that the affinity of peptide in this invention to gp120 was specific.

EXAMPLE 13: removal of HIV

from the serum by an HIV absorbing column

We prepared the removing and absorbing ability of HIV-1 by using the peptide/Sepharose 4B in this invention that was prepared in SYNTHESIS 9. The quantity of the peptide introduced in this invention that was conjugated to the above carrier was 5mg per 1ml in bed volume.

First, after 100 μ l of the above absorbed carrier was suspended in PBS(pH7.2) was added to a test tube, it was treated with an autoclave for 30 minutes at 121°C, and

decompressed naturally and the supplied sample was prepared. In addition, as a virus model of pseudo HIV-1, we used gp120 conjugated with colloidal gold solution that was prepared using a protein content of gp120 in 1.5mg/mL. The supplied virus solution, the pseudo HIV solution, was suspended with 100% human serum (96% as final content in serum), as a control the same content of pseudo HIV solution was suspended with PBS(pH 7.2, 0% human serum content). The supplied virus solution of 24(2.4mL) volume was added to a test tube with the antibody-like peptide of 1 volume(100 μ l), and was mixed by shaking in a water bus for 2 hours at 37°C. After the incubation, we took this test tube out and stood it for 30 minutes at room temperature, then, we collected the unabsorbed pseudovirus sample from this supernatant fluid. We measured the rate of absorption the sample of 540nm, which was provided in this way; the rate of the 94% serum against the absorption of the 0% serum (was calculated as 100% in TABLE 18). These results show in TABLE 18.

TABLE 18

Content of serum(%)	Rate of absorption(%)
0	100
94	74

EXAMPLE 14: removal of HIV from the serum

through the use of an HIV absorbing column

By using a carrier of cellulose series that covalented with the peptide in this invention prepared in SYNTHESIS 7, we examined the absorption and removal of HIV. At this time, the rate of peptide in this invention introduced here was about 5mg per

1mL of the bed volume.

First, 100 μ l of the above absorbed carrier suspended in PBS(pH7.2) was added to the test tube, it was treated with an autoclave for 30 minutes at 121°C, decompressed naturally, and was prepared as supplied sample. Another, HIV-1 virus solution was also used, kk-1 strain, this was freshly isolated from domestic AIDS patients by Ohtake et al.(Kansenshou zasshi(in Japanese), 64;1284-1294,1990) and frozen. After having rapidly defrosted this KK-1 strain (1×10^5 TCID₅₀), we ultra-centrifuged it and prepared the supplied sample that was suspended previously in 100% of inactivated human serum. Next, 1 bed volume then, 24 volume of the supplied virus solution were passed through the column. After the addition, we washed down the serum 5 times against the bed volume to expel the unbound virus that stayed in the column. The virus content was measured by using p24 Antigen ELISA Kit (Cellular products Inc.), we calculated S/CO from Cut Off value based on instructions attached to the kit. The samples measured were: the supplied sample (virus solution), the unbound sample, the washing solution, and extraction that lyzed binding virus from the carrier (fraction of absorbed column) by lyzing buffer, attached in the kit. The fraction that passed without binding to the column included both this unbound sample and the washing solution. These results are shown in TABLE 19.

TABLE 19

	p24(S/CO)
Virus solution(Starting materials)	2,350
Fraction of column without absorption(column passing solution without absorption)	2,209
Fraction of column absorption	205

From TABLE 19, we can understand easily that a little less than 10% of the supplied virus was absorbed by the column.

In the above EXAMPLE, we described the reason for the adopted measurement method of p24 content to evaluate the quantity of the virus.

In this example, we used KK-1 strain, freshly isolated and suspended in 100% human serum for the reason that it resembles the state of the virus in an AIDS patient. To evaluate the content correctly is very difficult. Even if it is usable in the gp120 ELISA Kit in the HIV laboratory strain, it cannot be used with a freshly isolated virus such as KK-1. Rather, this is the reason that we used this virus. Accordingly, we can measure p24 content by the EIA method where there is a core protein having a consensus sequence on first structure or measuring by the RT-PCR method. However, both methods have the weak point that they measure p24 including the debris. As mentioned above, HIV itself is very unstable and will be broken with time, even during operation. It is thought the debris exists already, and it will increase. Therefore, when the debris increases compared with content of the absorbed virus, we cannot understand the result, even if we adopted both methods. Accordingly, a judgment by an infection experiment is desirable in order to measure the content of the virus precisely. But, the freshly isolated KK-1 that was used in this example is difficult to infect compared with a laboratory strain such as HIV-1 IIIB etc. , and particularly, a virus solution of high density is needed, far exceeding the content of column absorption in the infection experiment. Considering these problems, it is very difficult to do the experiment. So, for the reason that it is difficult to measure the absorption content if the content is in a

dilute virus solution of this degree, we measured the p24 content in this example and calculated S/CO by comparing it with other data.

EXAMPLE 15: the binding of HIV

to latex conjugated peptide

We filmed the agglutination condition of HIV by No.2 virus/No.1peptide-latex beads in TABLE 17. In detail, after the HIV-1LAV1 laboratory strain was added to the above agglutinin test medicine, it stood for 6 hours at 4°C. Afterwards, this agglutinated solution was put on a support membrane for observation by electron microscope, it was negatively stained with uranyl acetate and a photograph was taken. Referentially, we show this photograph in Fig. 2

From Fig. 2, we can observe that the HIV virus binds tightly to the latex beads conjugated HIV-gp120 affinity peptide, those beads bind mutually and agglutinate.

INDUSTRIAL APPLICABILITY

As described above, the peptide in this invention is; superior in stability, an affinity to gp120, is extremely useful as a medicine to treat HIV as it has neutralizing activity equal to previous antibody molecules, can be used as to diagnose HIV through agglutination and is a medical tool for removing HIV. It has physical stability and is resistant to autoclave treatment, which is not so of antibody molecules.